- Home
- SVRA vs PCRX Comparison
SVRA vs PCRX Comparison
Compare SVRA & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRA
- PCRX
- Stock Information
- Founded
- SVRA N/A
- PCRX 2006
- Country
- SVRA United States
- PCRX United States
- Employees
- SVRA N/A
- PCRX N/A
- Industry
- SVRA Biotechnology: Pharmaceutical Preparations
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- SVRA Health Care
- PCRX Health Care
- Exchange
- SVRA Nasdaq
- PCRX Nasdaq
- Market Cap
- SVRA 458.2M
- PCRX 1.2B
- IPO Year
- SVRA N/A
- PCRX 2011
- Fundamental
- Price
- SVRA $2.85
- PCRX $26.59
- Analyst Decision
- SVRA Buy
- PCRX Buy
- Analyst Count
- SVRA 7
- PCRX 10
- Target Price
- SVRA $9.86
- PCRX $29.30
- AVG Volume (30 Days)
- SVRA 1.0M
- PCRX 892.8K
- Earning Date
- SVRA 03-06-2025
- PCRX 02-27-2025
- Dividend Yield
- SVRA N/A
- PCRX N/A
- EPS Growth
- SVRA N/A
- PCRX N/A
- EPS
- SVRA N/A
- PCRX N/A
- Revenue
- SVRA N/A
- PCRX $694,957,000.00
- Revenue This Year
- SVRA N/A
- PCRX $5.14
- Revenue Next Year
- SVRA N/A
- PCRX $2.44
- P/E Ratio
- SVRA N/A
- PCRX N/A
- Revenue Growth
- SVRA N/A
- PCRX 4.40
- 52 Week Low
- SVRA $2.59
- PCRX $11.16
- 52 Week High
- SVRA $5.70
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- SVRA 45.63
- PCRX 77.75
- Support Level
- SVRA $2.62
- PCRX $25.06
- Resistance Level
- SVRA $2.88
- PCRX $27.10
- Average True Range (ATR)
- SVRA 0.19
- PCRX 1.45
- MACD
- SVRA 0.02
- PCRX 0.28
- Stochastic Oscillator
- SVRA 40.37
- PCRX 86.23
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.